Phase 3 Endometrial Cancer Trial, Recruiting NCT07472153 Sponsor: N.N. Alexandrov National Cancer Centre Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 3 Endometrial Cancer Trial, Recruiting

NCT07472153
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 75 years old.
  • People who have a confirmed diagnosis of cervical cancer, proven through laboratory testing of tissue samples.
  • People whose cervical cancer falls into one of these three categories: cancer that has spread to distant parts of the body (stage IVB); cancer that could not be fully cleared after intensive treatment for advanced stages (stages IIB–IVA); or cancer that has come back for the first time after completing intensive treatment (any stage from IA to IVB).
  • People for whom a tissue sample is available to test for a protein called PD-L1, which is relevant for those being considered for immunotherapy.
  • People who have a good general level of physical functioning, rated as 0 or 1 on a standard medical scale (meaning fully active or able to carry out light activity).
  • People who have no medical reasons preventing them from receiving chemotherapy, immunotherapy, or a medication called bevacizumab.
  • People who have given signed consent to take part in the study.

Who may not be able to join:

  • People who currently have another active cancer of an invasive type.
  • People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 80259111218

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
N.N. Alexandrov National Cancer Centre
Registry
ClinicalTrials.gov
Start date
1 July 2025
Est. completion
30 June 2030

Where this trial is recruiting

Belarus

Primary endpoints

Overall survival; Median overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov